Trial Profile
Efficacy and security of certolizumab pegol treatment in patients with reumatoid arthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms Saitama East
- 10 Jul 2020 Status changed from not yet recruiting to discontinued.
- 02 Dec 2014 New trial record